American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.

Prolonged Improvement in PROs and Well-Being in Older Patients with Treatment-Naïve CLL Treated with Ibrutinib: 3-Year Follow-Up of the RESONATE-2 Study

ASH 2017 – CLL

In the RESONATE-2 study, treatment of older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia resulted in significantly improved patient-reported outcomes (PROs), disease burden, quality of life, medical resource utilization, and quality-adjusted survival time compared with those treated with chlorambucil. Read More ›

Addition of Midostaurin to Standard Chemotherapy in RATIFY Decreased CIR in Patients with FLT3-Mutated, Newly Diagnosed AML

ASH 2017 – AML

The results of a post-hoc analysis of the RATIFY trial suggest that midostaurin decreases the cumulative incidence of relapse (CIR) in patients with FLT3 mutation–positive, newly diagnosed acute myeloid leukemia (AML), with no negative impact on survival. Read More ›

Venetoclax plus Decitabine or Azacitidine in Treatment-Naïve, Elderly Patients with AML

ASH 2017 – AML

An updated safety and efficacy analysis of a phase 1b study demonstrated a promising benefit–risk profile with the combination of the BCL-2 inhibitor venetoclax with either decitabine or azacitidine in elderly, treatment-naïve patients with acute myeloid leukemia (AML) who are not candidates for intensive standard induction therapy. Read More ›

Lirilumab plus Azacitidine in Heavily Pretreated, Relapsed AML

ASH 2017 – AML

The results of the current phase 1b/2 study showed that the combination of azacitidine plus lirilumab was well-tolerated in heavily pretreated patients with relapsed acute myeloid leukemia (AML) and poor-risk disease features. Read More ›

Continuing Enasidenib Treatment Improves Survival and Responses for Mutant-IDH2 R/R AML Patients with Stable Disease

ASH 2017 – AML

An analysis of response and survival outcomes from the phase 1/2 AG221-C-001 study showed that continued treatment with enasidenib resulted in improved survival and response times in patients with mutant-IDH2 relapsed or refractory (R/R) acute myeloid leukemia (AML). Read More ›

Dual FLT3 and CDK4/6 Inhibition Shows Modest Activity in Relapsed/Refractory AML

ASH 2017 – AML

A phase 1 dose-escalation study of FLX925, a dual FLT3 and CDK4/6 inhibitor, showed modest antileukemic activity in adult patients with relapsed or refractory acute myeloid leukemia (AML). Read More ›

Nivolumab plus Azacitidine Shows Encouraging Activity in R/R AML or as Frontline Therapy in Elderly Patients with AML

ASH 2017 – AML

Combination treatment with nivolumab plus azacitidine produced encouraging response rates in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with poor-risk features, and in elderly patients as frontline therapy. Read More ›

Long-Term Follow-Up of ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel in Patients with Refractory, Aggressive NHL

ASH 2017 – CLL

In a 1-year follow-up of the ZUMA-1 study, axicabtagene ciloleucel (axi-cel; anti-CD19 CAR T) demonstrated significant clinical benefit with manageable adverse events in patients with refractory, aggressive non-Hodgkin lymphoma (NHL) and no curative treatment options, but loss of CD19 and gain of PD-L1 expression in tumors were identified as possible mechanisms of resistance following axi-cel treatment. Read More ›

Avatrombopag Superior to Placebo for the Treatment of Chronic ITP

ASH 2017 – ITP

Results of this randomized, placebo-controlled phase 3 trial showed that avatrombopag was superior to placebo in terms of the cumulative number of weeks with a platelet response, platelet response at day 8, and durability of platelet response in patients with refractory chronic immune thrombocytopenia (ITP). Read More ›

No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND

ASH 2017 – ITP

The current study found no clear evidence linking eltrombopag treatment and risk for cataract development/progression in patients with chronic immune thrombocytopenia (ITP). Read More ›

American Society of Hematology (ASH)

Page 25 of 44